国际泌尿系统杂志
國際泌尿繫統雜誌
국제비뇨계통잡지
International Journal of Urology and Nephrology
2015年
6期
907-910
,共4页
肾疾病%维生素D
腎疾病%維生素D
신질병%유생소D
Kidney Diseases%Vitamin D
目的 探讨活性维生素D对膜性肾病患者TRPC6与Podocalyxin表达的影响.方法 选择2014年1月至2015年1月来本院治疗的80例特发性膜性肾病患者,随机分为对照组与观察组,每组40例,对照组患者给予常规治疗,观察组在对照组的基础上给予活性维生素D(口服骨化三醇胶丸0.25 ～0.5μg/d),治疗12周;采用免疫荧光法测定肾穿刺活检组织TRPC6、Podocalyxin表达水平,比较两组患者治疗前后血肌酐SCr、尿素氮BUN、尿蛋白、足细胞、TRPC6、Podocalyxin变化.结果 两组患者经治疗后BUN、SCr、尿蛋白显著低于治疗前(P＜0.05),治疗后,观察组BUN、尿蛋白水平明显低于对照组(P＜0.05),观察组SCr水平低于对照组,差异无统计学意义(P＞0.05);治疗前,两组患者尿足细胞数显著高于正常对照组,肾小球足细胞密度显著低于正常对照组(P＜0.05),经治疗后,与治疗前比较,两组尿足细胞数明显降低,肾小球足细胞密度明显升高,(P＜0.05);治疗后观察组尿足细胞数显著低于对照组,肾小球足细胞密度显著高于对照组(P＜0.05),治疗后两组肾组织Podocalyxin表达水平增加,TRPC6表达水平降低,治疗后观察组TRPC6、Podocalyxin表达水平与对照组比较,有显著差异(P＜0.05).结论 活性维生素D可显著降低特发性膜性肾病患者尿蛋白,降低尿足细胞数,通过调控TRPC6、Podocalyxin表达,减小足细胞损伤.
目的 探討活性維生素D對膜性腎病患者TRPC6與Podocalyxin錶達的影響.方法 選擇2014年1月至2015年1月來本院治療的80例特髮性膜性腎病患者,隨機分為對照組與觀察組,每組40例,對照組患者給予常規治療,觀察組在對照組的基礎上給予活性維生素D(口服骨化三醇膠汍0.25 ～0.5μg/d),治療12週;採用免疫熒光法測定腎穿刺活檢組織TRPC6、Podocalyxin錶達水平,比較兩組患者治療前後血肌酐SCr、尿素氮BUN、尿蛋白、足細胞、TRPC6、Podocalyxin變化.結果 兩組患者經治療後BUN、SCr、尿蛋白顯著低于治療前(P＜0.05),治療後,觀察組BUN、尿蛋白水平明顯低于對照組(P＜0.05),觀察組SCr水平低于對照組,差異無統計學意義(P＞0.05);治療前,兩組患者尿足細胞數顯著高于正常對照組,腎小毬足細胞密度顯著低于正常對照組(P＜0.05),經治療後,與治療前比較,兩組尿足細胞數明顯降低,腎小毬足細胞密度明顯升高,(P＜0.05);治療後觀察組尿足細胞數顯著低于對照組,腎小毬足細胞密度顯著高于對照組(P＜0.05),治療後兩組腎組織Podocalyxin錶達水平增加,TRPC6錶達水平降低,治療後觀察組TRPC6、Podocalyxin錶達水平與對照組比較,有顯著差異(P＜0.05).結論 活性維生素D可顯著降低特髮性膜性腎病患者尿蛋白,降低尿足細胞數,通過調控TRPC6、Podocalyxin錶達,減小足細胞損傷.
목적 탐토활성유생소D대막성신병환자TRPC6여Podocalyxin표체적영향.방법 선택2014년1월지2015년1월래본원치료적80례특발성막성신병환자,수궤분위대조조여관찰조,매조40례,대조조환자급여상규치료,관찰조재대조조적기출상급여활성유생소D(구복골화삼순효환0.25 ～0.5μg/d),치료12주;채용면역형광법측정신천자활검조직TRPC6、Podocalyxin표체수평,비교량조환자치료전후혈기항SCr、뇨소담BUN、뇨단백、족세포、TRPC6、Podocalyxin변화.결과 량조환자경치료후BUN、SCr、뇨단백현저저우치료전(P＜0.05),치료후,관찰조BUN、뇨단백수평명현저우대조조(P＜0.05),관찰조SCr수평저우대조조,차이무통계학의의(P＞0.05);치료전,량조환자뇨족세포수현저고우정상대조조,신소구족세포밀도현저저우정상대조조(P＜0.05),경치료후,여치료전비교,량조뇨족세포수명현강저,신소구족세포밀도명현승고,(P＜0.05);치료후관찰조뇨족세포수현저저우대조조,신소구족세포밀도현저고우대조조(P＜0.05),치료후량조신조직Podocalyxin표체수평증가,TRPC6표체수평강저,치료후관찰조TRPC6、Podocalyxin표체수평여대조조비교,유현저차이(P＜0.05).결론 활성유생소D가현저강저특발성막성신병환자뇨단백,강저뇨족세포수,통과조공TRPC6、Podocalyxin표체,감소족세포손상.
Objectives To investigate the influence of active vitamin D in patients with membranous nephropathy on TRPC6 and Podocalyxin expression.Methods 80 cases of patients with membranous nephropathy from January 2014 to January 2015 in our hospital were selected,they were randomly divided into control group and the observation group,40 cases in each group,the patients in control group were treated with conventional therapy,and patients in observation group were given active vitamin D (calcitriol oral capsules 0.25 ～0.5 μg/d) on the basis of control group,12 weeks of treatment,the TRPC6,Podocalyxin expression in renal biopsy tissue were detected by using immunofluorescence,serum creatinine,urine protein,urinary podocytes,TRPC6,Podocalyxin change were compared before and after treatment.Results BUN,SCr,urinary protein in two groups after treatment were significantly lower than before treatment(P ＜0.05),BUN,urine protein in the observation group compared with control group,the differences were statistically significant (P ＜ 0.05),SCr had no significant change (P ＞ 0.05);before treatment,the number of urinary podocytes,glomerular podocyte density in two groups were significantly different from normal control group(P ＜0.05),compared with before treatment,urinary podocytes number podocyte density changed significantly (P ＜ 0.05),a significant difference in two groups (P ＜0.05);After treatment,Podocalyxin expression of tissue increased,lower TRPC6 expression levels decreased,after treatment TRPC6,Podocalyxin expression levels in observed group had significant difference compared with control group (P ＜ 0.05).Conclusions It shows that active vitamin D can significantly reduce patients with membranous nephropathy urine protein,reduced the number of cells in urine foot,by regulating the expression of TRPC6,Podocalyxin to reduce podocyte injury.
